Company intelligence / Profile preview

Oncoscience AG

Ownership: Private
Development stage: Phase 3

Overview

Oncoscience AG has been involved in late-stage clinical development of nimotuzumab for various cancers and has also worked on organ transplantation therapeutics and tumor tissue banking. The company’s lead program was a Phase III trial with nimotuzumab in Germany targeting oncology indications.[4] No recent clinical results are available.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodiesSmall moleculesBiologics
Industry: Biotech

Drug pipeline

1 asset

nimotuzumab

Phase 3

Indications: Pontine glioma, Non-small cell lung cancer, Breast cancer, Esophageal cancer, Cervical cancer, Prostate cancer, Head and neck cancer

Partnerships

YM BioSciences

Beyond the preview

Go deeper on Oncoscience AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncoscience AG.

Explore the full profile